George A - Search Results

1

The peritoneal cancer index as a predictor of complete cytoreduction at primary and interval cytoreductive surgery in advanced ovarian cancer.

Fagan PJ, Gomes N, Heath OM, Chandrasekaran D, Yao SE, Satchwell L, George A, Banerjee S, Sohaib A, Barton DP, Nobbenhuis M, Ind T, Butler J. Fagan PJ, et al. Among authors: george a. Int J Gynecol Cancer. 2023 Nov 6;33(11):1757-1763. doi: 10.1136/ijgc-2022-004093. Int J Gynecol Cancer. 2023. PMID: 37890875

2

BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.

Moschetta M, George A, Kaye SB, Banerjee S. Moschetta M, et al. Among authors: george a. Ann Oncol. 2016 Aug;27(8):1449-55. doi: 10.1093/annonc/mdw142. Epub 2016 Mar 31. Ann Oncol. 2016. PMID: 27037296 Free article. Review.

3

The integration of BRCA testing into oncology clinics.

Percival N, George A, Gyertson J, Hamill M, Fernandes A, Davies E, Rahman N, Banerjee S. Percival N, et al. Among authors: george a. Br J Nurs. 2016 Jun 23;25(12):690-4. doi: 10.12968/bjon.2016.25.12.690. Br J Nurs. 2016. PMID: 27345073 Free PMC article.

4

Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients.

George A, Riddell D, Seal S, Talukdar S, Mahamdallie S, Ruark E, Cloke V, Slade I, Kemp Z, Gore M, Strydom A, Banerjee S, Hanson H, Rahman N. George A, et al. Sci Rep. 2016 Jul 13;6:29506. doi: 10.1038/srep29506. Sci Rep. 2016. PMID: 27406733 Free PMC article.

5

The current status of PARP inhibitors in ovarian cancer.

McLachlan J, George A, Banerjee S. McLachlan J, et al. Among authors: george a. Tumori. 2016 Oct 13;102(5):433-440. doi: 10.5301/tj.5000558. Epub 2016 Sep 24. Tumori. 2016. PMID: 27716873 Review.

6

Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.

George A, Kaye S, Banerjee S. George A, et al. Nat Rev Clin Oncol. 2017 May;14(5):284-296. doi: 10.1038/nrclinonc.2016.191. Epub 2016 Dec 13. Nat Rev Clin Oncol. 2017. PMID: 27958297 Review.

7

Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.

George A, Kristeleit R, Rafii S, Michie CO, Bowen R, Michalarea V, van Hagen T, Wong M, Rallis G, Molife LR, Lopez J, Banerji U, Banerjee SN, Gore ME, de Bono JS, Kaye SB, Yap TA. George A, et al. Eur J Cancer. 2017 May;76:52-59. doi: 10.1016/j.ejca.2017.01.020. Epub 2017 Mar 6. Eur J Cancer. 2017. PMID: 28273485 Free article.

8

Olaparib and somatic BRCA mutations.

George A, Banerjee S, Kaye S. George A, et al. Oncotarget. 2017 Jul 4;8(27):43598-43599. doi: 10.18632/oncotarget.18419. Oncotarget. 2017. PMID: 28611314 Free PMC article. No abstract available.

9

The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole.

George A, McLachlan J, Tunariu N, Della Pepa C, Migali C, Gore M, Kaye S, Banerjee S. George A, et al. BMC Cancer. 2017 Jun 30;17(1):456. doi: 10.1186/s12885-017-3440-0. BMC Cancer. 2017. PMID: 28666422 Free PMC article.

10

The role of Cediranib in ovarian cancer.

Orbegoso C, Marquina G, George A, Banerjee S. Orbegoso C, et al. Among authors: george a. Expert Opin Pharmacother. 2017 Oct;18(15):1637-1648. doi: 10.1080/14656566.2017.1383384. Expert Opin Pharmacother. 2017. PMID: 28933580 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,925 results

Search Page

Filters